- Home
- NTHI vs ALDX Comparison
NTHI vs ALDX Comparison
Compare NTHI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- ALDX
- Stock Information
- Founded
- NTHI 2008
- ALDX 2004
- Country
- NTHI United States
- ALDX United States
- Employees
- NTHI N/A
- ALDX N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- NTHI Health Care
- ALDX Health Care
- Exchange
- NTHI Nasdaq
- ALDX Nasdaq
- Market Cap
- NTHI 142.5M
- ALDX 133.7M
- IPO Year
- NTHI N/A
- ALDX 2014
- Fundamental
- Price
- NTHI $7.24
- ALDX $2.15
- Analyst Decision
- NTHI
- ALDX Strong Buy
- Analyst Count
- NTHI 0
- ALDX 2
- Target Price
- NTHI N/A
- ALDX $9.50
- AVG Volume (30 Days)
- NTHI 108.1K
- ALDX 1.2M
- Earning Date
- NTHI 01-01-0001
- ALDX 05-14-2025
- Dividend Yield
- NTHI N/A
- ALDX N/A
- EPS Growth
- NTHI N/A
- ALDX N/A
- EPS
- NTHI N/A
- ALDX N/A
- Revenue
- NTHI $79,990.00
- ALDX N/A
- Revenue This Year
- NTHI N/A
- ALDX N/A
- Revenue Next Year
- NTHI N/A
- ALDX N/A
- P/E Ratio
- NTHI N/A
- ALDX N/A
- Revenue Growth
- NTHI 13.52
- ALDX N/A
- 52 Week Low
- NTHI $4.11
- ALDX $1.14
- 52 Week High
- NTHI $25.00
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- ALDX 38.93
- Support Level
- NTHI N/A
- ALDX $2.15
- Resistance Level
- NTHI N/A
- ALDX $2.30
- Average True Range (ATR)
- NTHI 0.00
- ALDX 0.15
- MACD
- NTHI 0.00
- ALDX 0.06
- Stochastic Oscillator
- NTHI 0.00
- ALDX 37.93
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.